MeiraGTx acquires AAV gene therapy company Vector Neurosciences for up to $24mm
MeiraGTx Holdings PLC acquired privately held fellow gene therapy biotech Vector Neurosciences Inc. in an all-stock transaction, issuing a total of 225k Class A ordinary shares (valued at $3mm) to Vector’s stockholders.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.